This kind of genetic roll of the dice increases the odds that at least some population of cells in the tumor will have the ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation ... Allison Institute and Institute for Data Science in Oncology – ...

Traditional Chinese medicine (TCM) remains a valuable source for drug discovery. From 1999 to 2021, over 3,000 clinical ...

QUT scientists have uncovered functionality of a genetic variant in the prostate specific antigen (PSA) gene to improve the current diagnostic test to help distinguish aggressive from non-aggressive ...

7MW4811 is developed with Mabwell's next-generation ADC technology (IDDC™) platform, and has demonstrated encouraging anti-tumor effects across a range of solid tumors, including lung, colorectal, ...

Tickets are available – and registration will be open right up until the day of the event – for the 2024 Protein Science in ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...

Developed by Ascentage Pharma, olverembatinib is the first China -approved third-generation BCR:ABL1 inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent ...

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the company's participation in four upcoming scientific and medical conferences, presenting on Seismic's emerging ...

About NX-5948: NX-5948 is an investigational, orally bioavailable degrader of BTK that is currently being evaluated in a ...